在儿科固体瘤中保持生育能力:儿童瘤学小组的报告
Kari Bjornard1,2, Allison Close3, Karen Burns4
1Department of Pediatrics, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Pediatric blood & cancer
|March 27, 2024
概括
儿童癌症治疗,特别是固体瘤的治疗,显著增加了生殖腺功能障碍和不孕症的风险. 这项研究提供了一个风险分层模型,以指导儿科患者的生育咨询和服务.
科学领域:
- 儿科瘤学 儿科瘤学
- 生殖内分泌学 生殖内分泌学
- 癌症的生存率 癌症的生存率
背景情况:
- 儿童固体瘤治疗存在巨大的淋巴腺功能障碍和不孕症的风险.
- 及时讨论生育风险在诊断,治疗变化和整个生存过程中至关重要.
研究的目的:
- 开发一种标准化的风险分层模型,用于用于前线儿童固体瘤治疗方案的淋腺毒性疗法.
- 改善对生育风险的评估和沟通,并促进对生育保护和生殖健康咨询的转诊.
主要方法:
- 从32个儿童瘤学小组 (COG) 的第三阶段前线固体瘤协议 (2000-2022) 中抽象的淋腺毒性疗法.
- 评估风险 (最小,显著,高) 基于治疗,性别和青春期状态,使用瘤生育协会儿科倡议网络 (PIN) 框架.
- 由于响应调整疗法和辐射领域,在风险分层方面存在已知的挑战.
主要成果:
- 显著的大多数协议 (65.6%) 包含至少一个具有高淋巴腺功能障碍风险的治疗臂.
- 拟议的风险分层模型旨在标准化跨学科的评估.
结论:
- 儿科固体瘤疗法经常具有高不孕症风险,需要标准化风险评估.
- 开发的模型可以增强儿童癌症患者的生育服务推和生殖健康咨询,并且可能在国际上具有普遍性.
相关概念视频
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...


